Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on May 19, 2014. The filing reports a specific corporate governance event regarding the appointment of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On May 19, 2014, Russell J. Cox was appointed to the newly-created position of Executive Vice President and Chief Operating Officer, effective immediately. Mr. Cox previously served as the Company's Executive Vice President and Chief Commercial Officer since March 2012. He has been with the company since July 2010, holding various senior management roles.
Guidance, Outlook, and Risks
The filing states there were no new compensatory or other material arrangements entered into, nor were there any grants or awards made to Mr. Cox in connection with his appointment. Existing compensatory arrangements and indemnification agreements are referenced in the Company's Annual Report on Form 10-K/A filed on April 28, 2014. No financial guidance, outlook, or specific risk factors are disclosed in this document.
Investor Verification Checklist
- Verify the effective date of Russell J. Cox's appointment as Chief Operating Officer (May 19, 2014).
- Confirm that no new compensation packages or equity awards were issued for this specific role change.
- Review the Company's Form 10-K/A filed on April 28, 2014, for details on Mr. Cox's existing compensation and indemnification agreements.
- Note that this filing contains no financial results; refer to quarterly or annual reports for financial metrics.